


Tumours of the kidney

>95% of kidney cancers have a **characteristic morphology** that can be classified as: clear cell, papillary, chromophobe renal cell carcinoma, and carcinoma of the collecting ducts of Bellini.

Patient outcome varies between histological kidney cancer subtypes and is dependent on the treatment given.

Only a few kidney cancers have an unusual morphology and have been categorised as **rare kidney cancer entities**, e.g. mucinous tubular and spindle cell carcinoma.



Clinical and Pathological Classification of the Primary Tumour (pT)

| | |
|-----------|--------------------------------------------------------------------|
| T1 | Tumour 7 cm or less in greatest dimension, limited to the kidney |
| T2 | Tumour more than 7 cm in greatest dimension, limited to the kidney |
| T3 | Tumour extends into major veins or perinephric tissues |
| T4 | Tumour invades beyond Gerota fascia |

Primary tumour category has a strong prognostic impact.

Histological tumour grade (mostly performed according to Thoenes or Fuhrman) is more subjective and has less prognostic influence.


Criteria for a **high (unfavourable) grade** generally include a large nucleus size, polymorphy of the nuclei, presence of prominent nucleoli, and mitoses.

5%-7% of kidney tumours are benign. **Oncocytoma** is the most frequent benign tumour. The tumour is well circumscribed, mahogany brown with a central scar.

Angiomyolipomas represent 1% of kidney tumours. They consist of varying proportions of mature fat, thick-walled blood vessels, and smooth muscle.

Multilocular cystic carcinoma is in principle a malignant tumour but is entirely composed of cysts, with very few cancer cells. Metastases have not been reported.

"Benign" renal tumours



Oncocytoma

Angiomyolipoma

Multilocular cystic renal cell carcinoma

REVISION QUESTIONS

1. What are the main subtypes of renal cell carcinoma?
2. What is the best predictor of prognosis in renal cell carcinoma?
3. Which carcinoma has the best prognosis?

Tumours of the urinary system

Urothelium is present in the kidney pelvis, ureters, urinary bladder, and the urethra.

Urothelial neoplasms can occur in **all of these organs** but >90% are in the urinary bladder.

The normal **bladder wall** consists of several tissue layers, the distinction of which is critical for bladder cancer staging.





Diagram showing the T stages of bladder cancer



The urothelium covers the inner surface of the bladder. The connective tissue layer between the urothelium and the muscular bladder wall is the **lamina propria**.

The **staging system** of urothelial neoplasms is unusual as two non-invasive lesions exist: non-invasive papillary carcinoma (pTa) and carcinoma in situ (pTis).

The **invasive stages** are pT1: invasion of lamina propria; pT2: invasion of muscular wall; pT3: invasion of perivesical fat; pT4: invasion of adjacent organs.

Staging of bladder neoplasms is critical for treatment decisions, but **challenging for pathologists**.

This is due to the nature of transurethral tumour resection, because it always leads to **fragmentation and substantial crush artefacts** in the removed tissues.

The distinction between **pTa and pT1** tumour can be very challenging and is subject to high interobserver variability.

pTa versus pT1: High Interobserver Variability

pTa

Round regular epithelial nests - no invasion of lamina propria

pT1

Small irregular epithelial nests - invasion of lamina propria

| Author | N | pT1 | downstaged to pTa |
|-------------|-----|-----|-------------------|
| Abel 1988 | 28 | | 25% |
| Witjes 1994 | 120 | | 31% |
| Tosoni 2001 | 235 | | 34% |

Assessment of interobserver variability of staging pTa and pT1 tumours: In these studies pT1 tumours were reviewed and the initial diagnosis was downstaged to pTa in 25%-34% of cases.

REVISION QUESTIONS

1. What is the most common site for urothelial cancer?
2. What is the difference between stage pTa and pTis?
3. Which tumour stages are subject to particularly high interobserver variability?


Tumours of the urinary system

Development and progression of urothelial neoplasia occurs through **two quite different genetic pathways**.

Non-invasive papillary cancers of low/intermediate grade (pTa, G1/2) develop from dysplasia/hyperplasia and almost never progress to invasive cancer.


Invasive carcinomas are mostly of high grade and are mainly derived from carcinoma in situ or high-grade non-invasive papillary carcinomas (pTa, G3).

Model of bladder cancer development and progression based on genetic findings



NILGC = non-invasive low-grade carcinoma;
NIHGC = non-invasive high-grade carcinoma

Non-invasive papillary tumours



The classification of non-invasive papillary carcinomas is confusing because **two “non-congruent” systems** are typically used, either alone or in parallel.


Most clinicians are familiar with the **WHO 1973** grading system that classifies non-invasive cancers as pTaG1, pTaG2, or pTaG3.

The **WHO 2004** version also includes: papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), non-invasive papillary cancer, low grade, and non-invasive bladder cancer, high grade.

The term **“superficial bladder cancer”** is used for pTa and pT1 tumours.

pTa and pT1 tumours not only represent two different entities at the genetic level, but also have a completely **different clinical course**.

While pTa tumours rarely progress, **pT1 tumours are early stages of highly malignant neoplasms**.



REVISION QUESTIONS

1. What are the two main groups of urothelial neoplasms?
2. What is the difference between the WHO 1973 and WHO 2004 classification?
3. Why should the term “superficial bladder cancer” be avoided?

Tumours of the prostate


Prostate cancer is very common. A complete examination of the prostate will reveal cancer in 50% of men at the age of 50 and >75% at the age of 75 years.

Accordingly, **precursor lesions** are even more common in the prostate and many patients have more than one spatially separated prostate cancer.

Normal prostate epithelium is characterised by the presence of two cell layers: basal cells and acinar cells.


Prostate cancer is often multifocal
(Whole section through the prostate gland; blue arrow: prostate cancer, yellow circle: urethra)

Normal prostate gland



Clinical and Pathological Classification of the Primary Tumour T

- T1 Clinically unapparent tumour
- T2 Tumour confined within the tumour
- T3 Tumour extends through the prostatic capsule
- T4 Tumour invades adjacent structures other than seminal vesicles



Prostate biopsy is the only tool for establishing a **definitive diagnosis** of prostate cancer.


Findings in **prostate biopsies** include: normal, prostatic intraepithelial neoplasia (PIN), atypical small acinar proliferation (ASAP), and carcinoma.

PIN is the precursor lesion of prostate cancer. **ASAP** is a diagnostic category that includes all changes that are suspicious for cancer but not unequivocally diagnostic.

Prostate cancer is entirely composed of atypical cells, while basal cells are completely lost. **Gleason grade** is the strongest predictor of tumour aggressiveness.

In contrast to all other grading systems, the Gleason grade is purely based on **tumour architecture** and does not consider any cytological changes.

It distinguishes **5 sets of histological patterns** with increasing “dedifferentiation” from 1 to 5.



REVISION QUESTIONS


1. What is the precursor lesion of prostate cancer?
2. What is the meaning of “ASAP” and when is this term used?
3. What is the characteristic of Gleason grading?

Tumours of the testis


More than 95% of all testicular neoplasias are **germ cell tumours**. Germ cell tumours mostly occur at young age (highest frequency at the age of 30 years).

More than 90% of these develop through **intratubular germ cell neoplasia** (IGCNU), which is commonly found in the vicinity of these cancers.

50% of IGCNU progress into **invasive** germ cell tumours within 5 years.



Model of development of germ cell tumours



Seminoma is the least differentiated (earliest) development stage of invasive germ cell carcinoma.

About 50% of all testicular germ cell tumours halt at that stage of development and are diagnosed as **pure seminomas**.

Teratoma in the adult is a “differentiated type” of germ cell tumour having evolved from IGCNU and seminoma. Teratoma in the adult is thus considered malignant.

Tumour stage (pT) is critical for subsequent therapy of testicular tumours.

Most pT2 stages are diagnosed because of **vascular invasion**.

Regional lymph nodes include the abdominal, paraaortic, preaortic, interaortocaval, precaval, paracaval, retrocaval, and retroaortic nodes.

Clinical and Pathological Classification of the Primary Tumour T

- | | |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T1 | Tumour limited to testis and epididymis <u>without</u> vascular/lymphatic invasion |
| T2 | Tumour limited to testis and epididymis <u>with</u> vascular/lymphatic invasion or tumour extending through tunica albuginea with involvement of tunica vaginalis |
| T3 | Tumour invades spermatic cord |
| T4 | Tumour invades scrotum |

REVISION QUESTIONS

1. What is the precursor lesion of most germ cell tumours?
2. What is the typical age of patients with germ cell tumours?
3. Why is a testicular teratoma in an adult considered malignant?

Summary: Anatomy of the GU tract and histology of GU tumours

- The most common kidney cancers are clear cell, papillary, and chromophobe renal cell carcinoma
- Urothelium is present in the renal pelvis, ureters, urinary bladder, and the urethra, but >90% of urothelial neoplasms occur in the urinary bladder
- The staging system of urothelial neoplasms is unusual as two non-invasive lesions exist: pTa and pTis
- There is a high interobserver variability in staging pTa and pT1 tumours
- pTa and pT1 tumours represent two different entities at the genetic level and have a completely different clinical course
- Prostate cancer is very common, >75% of men at the age of 75 years will reveal prostate cancer
- Prostate cancer is graded according to Gleason grading, the strongest predictor of tumour aggressiveness
- More than 95% of all testicular neoplasias are germ cell tumours
- Germ cell tumours mostly occur at young age
- Germ cell tumours include seminoma, embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma

Further Reading

Comp rat E, Camparo P, Srigley J, et al. ISUP Consensus Working Group. International Society of Urological Pathology (ISUP) Consensus Conference on handling and staging of radical prostatectomy specimens [In French]. *Ann Pathol* 2013; 33:155–161.

Epstein JI, Allsbrook WC Jr, Amin MB, et al; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol* 2005; 29:1228–1242.

Epstein JI. Precursor lesions to prostatic adenocarcinoma. *Virchows Arch* 2009; 454:1–16.

Gerlinger M, Catto JW, Orntoft TF, et al. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. *Eur Urol* 2015; 67:729–737.

Looijenga LH, Gillis AJ, Stoop H, et al. Dissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance. *Int J Androl* 2011; 34:e234–251.

Looijenga LH, Stoop H, Biermann K. Testicular cancer: biology and biomarkers. *Virchows Arch* 2014; 464:301–313.

Moch H, Srigley J, Delahunt B, et al. Biomarkers in renal cancer. *Virchows Arch* 2014; 464:359–365.

Sauter G, Mihatsch MJ. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! *J Pathol* 1998; 185:339–341.

Srigley JR, Delahunt B, Eble JN, et al; ISUP Renal Tumour Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol* 2013; 37:1469–1489.

Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. *BJU Int* 2000; 85:48–53.